ADE in the context of chemotherapy is an acronym generally accepted in oncohematology for one of the chemotherapy regimens , often used as an induction or consolidation regimen in acute myeloid leukemia , especially in patients at high risk or in relapse or refractory to standard first-line induction chemotherapy - regimen " 7 +3 ".
ADE mode consists of three drugs:
- Cytarabine - A ra-C - antimetabolite ;
- Daunorubicin - D aunorubicin - an anthracycline antibiotic that has the ability to intercalate DNA , thereby disrupting cell division and preventing mitosis ;
- Etoposide - E toposide - topoisomerase inhibitor . [one]
Dosage
| Medicine | Dose | Route of administration | Days |
|---|---|---|---|
| Cytarabine - (A) ra-C | 200 mg / m 2 | Intravenous bolus every 12 hours in divided doses (100 mg / m 2 each) | Days 1-10 |
| Daunorubicin - (D) aunorubicin | 50 mg / m 2 | Slowly intravenously | Days 1, 3, and 5 |
| Etoposide - (E) toposide | 100 mg / m 2 | Intravenous infusion for 1 hour | Days 1-5 |